Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

Nonetheless, it's a big green flag for the biotech's stock that a hungry giant like Novo Nordisk is willing to make such a substantial financial commitment to see what it can do. Similarly ...

Wednesday's edition of Forbes Daily covers TikTok whistleblower claims, the S&P's latest high, Trump's new crypto venture, ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ...